USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
XCYTE THERAPIES, INC.
Address:
XCYTE THERAPIES, INC.
2203 AIRPORT WAY S, STE 300
SEATTLE, WA 98134
Phone:
(206) 328-7250
URL:
N/A
EIN:
911707622
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $157,022.00 2
SBIR Phase II $1,167,553.00 1

Award List:

AUTOLOGOUS T CELL THERAPY FOR B-CLL

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$157,022.00
Agency:
HHS
Principal Investigator:
Mark L. Bonyhadi
Abstract:
Not Available In order to be used in future infrared countermeasures systems, the cost of current diode pumped solid state lasers and mid-infrared parametric oscillators must be reduced and the size of the laser head must be significantly reduced. The proposed Phase I research will develop an… More

Autologous T Cell Therapy for CLL

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Xcyte Therapies has developed a process ("Xcellerate") for the ex vivo activation and expansion of T cells using magnetic beads coated with antibodies to CD3 and CD28. Xcellerated T Cells from patients with CLL demonstrate an enhanced T cell repertoire, and the… More

Autologous T Cell Therapy for CLL

Award Year / Program / Phase:
2003 / SBIR / Phase II
Award Amount:
$1,167,553.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Xcyte Therapies has developed a process ("Xcellerate") for the ex vivo activation and expansion of T cells using magnetic beads coated with antibodies to CD3 and CD28. Xcellerated T Cells from patients with CLL demonstrate an enhanced T cell repertoire, and the… More